Core Viewpoint - Baiaosaitu-B (02315) has seen a significant increase in stock price, rising nearly 7% and currently trading at 39.72 HKD, with a transaction volume of 28.32 million HKD. The company has completed the localization of its AI-driven antibody drug development platform, enhancing synergy with its core business, the "Thousand Mice and Ten Thousand Antibodies" initiative [1]. Group 1 - The company has successfully localized its AI-driven antibody drug development platform [1]. - The integration of the AI system with the "Thousand Mice and Ten Thousand Antibodies" plan is ongoing, which is expected to provide more efficient research tools and a richer antibody molecule library for global pharmaceutical companies [1]. - This development aims to improve the efficiency of preclinical PCC molecule research for pharmaceutical partners, marking a new phase in the antibody discovery business [1].
港股异动 | 百奥赛图-B(02315)再涨近7% 公司已完成AI驱动抗体药物研发平台的本地化部署